Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 35

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 35
---
 approving the Business Combination;                                   |

| • |     | those factors set forth in documents of Denali filed, or to be filed, with SEC; and |

| • |     | other factors detailed under the section titled “Risk Factors.” |

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of Denali and Semnur prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. All subsequent written and oral forward-looking statements concerning the Business Combination or other matters addressed in this proxy statement/prospectus and attributable to Denali, Semnur or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this proxy statement/prospectus. Except to the extent required by applicable law or regulation, Denali and Semnur undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this proxy statement/prospectus or to reflect the occurrence of unanticipated events. 7

QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE MEETING The following are answers to some questions that you, as a shareholder of Denali, may have regarding the Business Combination and the Meeting. We urge you to read carefully the remainder of this proxy statement/prospectus because the information in this section does not provide all the information that might be important to you with respect to the Proposals and the other matters being considered at the Meeting. Additional important information is also contained in the annexes to and the documents incorporated by reference into this proxy statement/prospectus. QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION

| Q: | What will happen in the Business Combination? |

| A: | Denali, Merger Sub, and Semnur have agreed to the Business Combination under the terms of the Merger Agreement,                                                                                                                                    
 Amendment No. 1 to Merger Agreement and Amendment No. 2 to Merger Agreement, which are attached to this proxy statement/prospectus as Annex A-1, Annex A-2 and Annex A-3, respectively, and are incorporated into this proxy                       
 statement/prospectus by reference. Pursuant to the Merger Agreement, prior to the Effective Time, Denali will change its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a 
 corporation incorporated under the laws of the State of Delaware. See “Proposal 2 — The Domestication Proposal”